Cancer – AHOD1221: Phase 1/2 Trial of Brentuximab Vedotin in Combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma
Condition or Therapy:
Recurrent adult Hodgkin lymphoma
Cancer and blood disorders
Study Number: AHOD1221
What is the goal of this study?
This study looks at how the combination of brentuximab vedotin and gemcitabine hydrochloride work in treating patients with recurrent or refractory Hodgkin lymphoma.
Who can join the study?
This study may be a good fit children and young adults who:
- are between 13 months and 30 years old and
- have returned or refractory Hodgkin lymphoma.
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.